Feminizing adrenocortical carcinoma in a postmenopausal woman

B, Barceló Lucerga; Abascal, José M.; Ardáiz, J; Gil, Pedro; Colas, Aurélie; Menéndez, J. Noval; Inchausti, J. L.

doi:10.1136/pgmj.55.644.406

Cited by 12 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In men the consultation motive was gynecomastia, but some complained from back or abdomen pain, sexual troubles, but rarely from high blood pressure (HBP) with or without heart failure. [ 4 ] Women usually complain from postmenopausal genital bleeding[ 23 ] or from HBP. [ 20 ]…”

Section: Ircumstances Of D mentioning

confidence: 99%

“…In women, apart from genital bleeding[ 23 ] with or without increased libido, uterus hypertrophy[ 23 ] and/or HBP maybe the only manifestations. Hepatomegaly and lower limb edema maybe observed too.…”

Section: Linical P Rofilementioning

confidence: 99%

“…The last condition is very rare and the prognosis is deemed to be the worst. In literature only single cases have been reported in adults[ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 19 21 22 23 24 25 25 ] and in pediatric population. [ 19 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 ] The largest published series does not exceed two[ 7 25 ] and three cases.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Feminizing adrenocortical tumors: Literature review

Chentli

Bekkaye

Azzoug

2015

Indian J Endocr Metab

View full text Add to dashboard Cite

Feminizing adrenal tumors (FAT) are extremely rare tumors prevailing in males. Clinical manifestations are gynecomastia and/or other hypogonadism features in adults. They are rarer in pediatric population and their main manifestation is peripheral sexual precocity.In women genital bleeding, uterus hypertrophy, high blood pressure and/or abdomen mass may be the only manifestations.On the biological point, estrogen overproduction with or without increase in other adrenal hormones are the main abnormalities. Radiological examination usually shows the tumor, describes its limits and its eventual metastases. Adrenal and endocrine origins are confirmed by biochemical assessments and histology, but that one is unable to distinguish between benign and malignant tumors, except if metastases are already present. Immunostaining using anti-aromatase antibodies is the only tool that distinguishes FAT from other adrenocortical tumors. Abdominal surgery is the best and the first line treatment. For large tumors (≥10 cm), an open access is preferred to coeliosurgery, but for the small ones, or when the surgeon is experienced, endoscopic surgery seems to give excellent results. Surgery can be preceded by adrenolytic agents such as ortho paraprime dichloro diphenyl dichloroethane (Mitotane), ketoconazole or by aromatase inhibitors, but till now there is not any controlled study to compare the benefit of different drugs. New anti-estrogens can be used too, but their results need to be confirmed in malignant tumors resistant to classical chemotherapy and to conventional radiotherapy. Targeted therapy can be used too, as in other adrenocortical tumors, but the results need to be confirmed.

show abstract

Section: Ircumstances Of D mentioning

confidence: 99%

Section: Linical P Rofilementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Feminizing adrenocortical tumors: Literature review

Chentli

Bekkaye

Azzoug

2015

Indian J Endocr Metab

View full text Add to dashboard Cite

show abstract

“…Most cases occur between 24 and 45 years in men. 54,55 The criteria for confirmation of pure estrogen-producing ACC remains controversial elevation of serum estrogen levels indicates extraglandular aromatization of adrenal steroid precursors. Secretion of estrogen in ACC requires the local expression of aromatase and 17 b-hydroxysteroid dehydrogenase.…”

Section: Androgen-producing Adrenocortical Carcinomamentioning

confidence: 99%

Adrenocortical Carcinoma

Nakamura

Yamazaki

Felizola

et al. 2015

Endocrinology and Metabolism Clinics of North America

View full text Add to dashboard Cite

“…Their frequency seems more important in men over 70 (7%) than in those under 30 years old (1%). They are very rare in women[10] and children,[51112] and exceptional in newborns. [13]…”

Section: Discussionmentioning

confidence: 99%

Feminizing adrenal tumors: Our experience about three cases

Chentli

Bekkaye

Yahiaoui

et al. 2013

Indian J Endocr Metab

View full text Add to dashboard Cite

Feminizing adrenal tumors (FATs) are very rare as they account for less than 2% of all the adrenal neoplasms. Their prognosis is deemed to be very poor. We aimed to present a mono centre (adult and pediatric) experience over a long period of time (January 1980 to Jun 2012). During the study period, we observed only three cases in men aged 22 (2 cases) and 45 (1 case). They all consulted for a painful gynecomastia, decreased libido and impotency. Estradiol was high in two cases at presentation, and after a relapsing tumor in the third one. All had big adrenal tumors (5.9, 6, and 17 cm), and a mixed secretion composed by high estradiol and cortisol. The pathological study argued for malignancy in two cases. But, only one had diffuse metastasis and died 4 years after diagnosis; the others diagnosed one and three years ago are still alive without any metastasis or relapsing.

show abstract

Feminizing adrenocortical carcinoma in a postmenopausal woman

Cited by 12 publications

References 9 publications

Feminizing adrenocortical tumors: Literature review

Feminizing adrenocortical tumors: Literature review

Adrenocortical Carcinoma

Feminizing adrenal tumors: Our experience about three cases

Contact Info

Product

Resources

About